CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 130 enrolled
Drug / intervention
Hydroxychloroquine (HCQ)drug
Likely dose
Hydroxychloroquine (HCQ) 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04354870
NCT04354870Phase 2Completed
CompareCT.gov

Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2

NYU Langone Health·interventional·Posted Apr 21, 2020·Updated Dec 14, 2022

In Brief

A Phase 2 clinical trial evaluating Hydroxychloroquine (HCQ) for COVID-19. Completed, enrolled 130 participants across 1 site.

Detailed Summary

Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 350 participants will be assigned to the group that takes HCQ or the group that opts to not take the study medication. Participants will be NYULH HCW at high risk for occupational exposure to SARS-CoV-2. Study timepoints will include screening/enrollment, 30 day, 60 day, and 90 day visits. Questionnaires, and DBS will be collected in all timepoints.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 21, 2020
Enrollment StartApr 3, 2020
Primary CompletionSep 15, 2020
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.2 years ago

Interventions

Hydroxychloroquine (HCQ)drug

Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days